ID   NB1
AC   CVCL_1440
SY   NB-1; NB-I; NB 1
DR   BTO; BTO:0005103
DR   CLO; CLO_0051419
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 402
DR   BioSample; SAMN03470966
DR   BioSample; SAMN03472043
DR   BioSample; SAMN10988531
DR   cancercelllines; CVCL_1440
DR   Cell_Model_Passport; SIDM00578
DR   CGH-DB; 74-1
DR   CGH-DB; 9097-4
DR   Cosmic; 801736
DR   Cosmic; 920243
DR   Cosmic; 947696
DR   Cosmic; 949179
DR   Cosmic; 1037339
DR   Cosmic; 1099136
DR   Cosmic; 1153784
DR   Cosmic; 1526632
DR   Cosmic; 2131573
DR   Cosmic-CLP; 949179
DR   DepMap; ACH-000804
DR   EGA; EGAS00001000978
DR   GDSC; 949179
DR   GEO; GSM333816
DR   GEO; GSM333825
DR   GEO; GSM887348
DR   GEO; GSM888425
DR   GEO; GSM1670145
DR   GEO; GSM2371241
DR   GEO; GSM2394388
DR   GEO; GSM4104581
DR   GEO; GSM4104582
DR   IARC_TP53; 27699
DR   JCRB; IFO50295
DR   JCRB; JCRB0621
DR   LiGeA; CCLE_099
DR   LINCS_LDP; LCL-1977
DR   PharmacoDB; NB1_984_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1440
DR   RCB; RCB1953
DR   TKG; TKG 0486
DR   Wikidata; Q54907515
RX   CelloPub=CLPUB00086;
RX   PubMed=174024;
RX   PubMed=201151;
RX   PubMed=590688;
RX   PubMed=4144593;
RX   PubMed=9290701;
RX   PubMed=11129446;
RX   PubMed=12210830;
RX   PubMed=12702577;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 40-50 hours (PubMed=174024); ~1 day (Note=Lot 12092005), ~32 hours (Note=Lot 09252019) (JCRB=IFO50295); ~60 hours (Note=Lot 120898), ~2 days (Note=Lot 08152016) (JCRB=JCRB0621).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.29%; Native American=0.21%; East Asian, North=80.53%; East Asian, South=13.17%; South Asian=0%; European, North=0%; European, South=3.8% (PubMed=30894373).
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,13
ST   D16S539: 9 (Cosmic-CLP; JCRB; PubMed=25877200; TKG)
ST   D16S539: 9,12 (RCB)
ST   D18S51: 16
ST   D19S433: 13.2,15.2
ST   D21S11: 30,31.2
ST   D2S1338: 17,27
ST   D3S1358: 15,17
ST   D5S818: 9,11
ST   D7S820: 8,12 (Cosmic-CLP; JCRB; PubMed=25877200; RCB)
ST   D7S820: 12 (TKG)
ST   D8S1179: 12,16
ST   FGA: 19,23
ST   Penta D: 8,9
ST   Penta E: 17,18
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 16,19
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y3M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   CelloPub=CLPUB00086;
RA   Miyake S., Shimo T., Kitamura Y., Nojyo T., Nakamura S., Imashuku S.,
RA   Abe T.;
RT   "Characteristics of continuous and functional cell line NB-I, derived
RT   from a human neuroblastoma.";
RL   Jiritsu Shinkei 10:115-120(1973).
//
RX   PubMed=174024;
RA   Miyake S., Kitamura T., Shimo Y.;
RT   "Morphological differentiation in vitro of human continuous and
RT   functional neuroblastoma cell line, NB-I under treatment of
RT   (But)2cAMP.";
RL   No Shinkei Geka 3:407-414(1975).
//
RX   PubMed=201151; DOI=10.1111/j.1440-1827.1977.tb00186.x;
RA   Ishikawa S.;
RT   "Differentiation of human neuroblastoma cells in vitro--morphological
RT   changes induced by dibutyrl cyclic AMP.";
RL   Acta Pathol. Jpn. 27:697-711(1977).
//
RX   PubMed=590688; DOI=10.20772/cancersci1959.68.5_711;
RA   Ohnuma N., Kasuga T., Nojiri I., Furuse T.;
RT   "Radiosensitivity of human neuroblastoma cell line (NB-1).";
RL   Gann 68:711-712(1977).
//
RX   PubMed=4144593; DOI=10.1210/jcem-36-5-931;
RA   Imashuku S., Inui A., Nakamura T., Tanaka J., Miyake S.;
RT   "Catecholamine metabolism in tissue culture cells of a
RT   neuroblastoma.";
RL   J. Clin. Endocrinol. Metab. 36:931-936(1973).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11129446; DOI=10.1097/00019606-200012000-00007;
RA   Sugimoto T., Mine H., Horii Y., Takahashi K., Nagai R., Morishita R.,
RA   Komada M., Asada Y., Sawada T.;
RT   "Neuroblastoma cell lines showing smooth muscle cell phenotypes.";
RL   Diagn. Mol. Pathol. 9:221-228(2000).
//
RX   PubMed=12210830; DOI=10.1002/jnr.10330;
RA   Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.;
RT   "Malignant rhabdoid tumor shows incomplete neural characteristics as
RT   revealed by expression of SNARE complex.";
RL   J. Neurosci. Res. 69:642-652(2002).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//